Sepsis Therapy Trials: Continued Disappointment or Reason for Hope?

JAMA: The Journal of the American Medical Association

Volumn 271, Issue 23, 1994, Pages 1876-1878

  Abraham, Edward ^a   Raffin, Thomas A ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; HUMAN; MORTALITY; PRIORITY JOURNAL; SEPSIS; SURVIVAL TIME;

EID: 0028305204     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1994.03510470080040     Document Type: Article

References (11)

1. Okusawa S, Gelfan JA, Ikejima T, et al. Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988;81:1162-1172.
2. Calandra T, Baumgartner J-D, Grau GE, et al. Prognostic value of tumor necrosis factor/cachectin, interleukin-1, interferon-α, and interferon-γin the serum of patients with septic shock. J Infect Dis. 1990;161:982-987.
3. Ohlsson K, Bjork P, Bergenfeldt M, et al. An interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 1990;348:550-552.
4. Fischer E, Marano MA, VanZee KJ, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in E. coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest. 1992;89:1551-1557.
5. Fisher CJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled trial. Crit Care Med. 1994;22:12-21.
6. Fisher CJ Jr, Dhainaut J-F A, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA. 1994;271:1836-1843.
7. Greenman RL, Schein RM, Marin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA. 1991;266:1097-1102.
8. Zeigler EJ, Fisher CJ, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med. 1991;324:429-436.
9. Tenaillon A, Dhainaut JF, Letulzo Y, et al. Efficacy of PAF antagonist (BN 52021) in reducing mortality of patients with severe gram-negative sepsis. Am Rev Respir Dis. 1993;147:A97.
10. Knaus WA, Harrell FE, Fisher CJ Jr, et al. The clinical evaluation of new drugs for sepsis: a prospective study design based on survival analysis. JAMA. 1993;270: 1233-1241.
11. Wherry J, Wenzel R, Abraham E, et al. A controlled randomized double blind clinical trial of monoclonal antibody to human tumor necrosis factor (TNF MAb) in patients with sepsis syndrome. Chest. 1993;104:35.